Angiotensin II Blockade and Total Cardiovascular Risk

No abstract is available for this paper.

• Publication year

  2008

• Venue

  High Blood Pressure & Cardiovascular Prevention

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/0151642-200815040-00004PMID 23355127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiotensin AT2 Receptor Ligands

  2012cited by this paper
• Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System

  2012cited by this paper
• No HOPE without proof: do ARBs meet the standard for cardiovascular protection?

  2008cited by this paper
• Risk‐Based Classification of Hypertension and the Role of Combination Therapy

  2008cited by this paper
• Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.

  2008cited by this paper
• Endothelial effects of antihypertensive treatment: focus on irbesartan

  2008cited by this paper
• Management of hypertension in patients with chronic kidney disease and diabetes mellitus.

  2008cited by this paper
• Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

  2008cited by this paper
• Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.

  2007cited by this paper
• Losartan Improves the Impaired Function of Endothelial Progenitor Cells in Hypertension via an Antioxidant Effect

  2007cited by this paper
• Regulation of the renin–angiotensin system in coronary atherosclerosis: A review of the literature

  2007cited by this paper
• Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

  2007cited by this paper
• Obesity, essential hypertension and renin–angiotensin system

  2007cited by this paper
• Restoring the dysfunctional endothelium.

  2007cited by this paper
• Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone

  2007cited by this paper
• Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.

  2007cited by this paper
• Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes

  2007cited by this paper
• The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome.

  2006cited by this paper
• Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.

  2006cited by this paper
• Endothelial Protection, AT1 Blockade and Cholesterol-Dependent Oxidative Stress: The EPAS Trial

  2006cited by this paper
• Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria

  2006cited by this paper
• The metabolic syndrome and chronic kidney disease

  2006cited by this paper
• Neuroprotection with Angiotensin Receptor Antagonists

  2005cited by this paper
• Treating Hypertension With Cardioprotective Therapies: The Role of ACE Inhibitors, ARBs, and β‐Blockers

  2005cited by this paper
• Pathophysiology of Coronary Artery Disease

  2005cited by this paper
• Beyond blood pressure: endothelial protection against hypercholesterolemia by angiotensin II type-1 receptor blockade.

  2005cited by this paper
• Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)

  2005cited by this paper
• The cardiovascular continuum and renin–angiotensin–aldosterone system blockade

  2005cited by this paper
• Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis

  2004cited by this paper
• Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.

  2004cited by this paper
• Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?

  2004cited by this paper
• Hypercholesterolemia Stimulates Angiotensin Peptide Synthesis and Contributes to Atherosclerosis Through the AT1A Receptor

  2004cited by this paper
• Endothelial dysfunction and oxidative stress in chronic renal failure.

  2004cited by this paper
• Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients.

  2004cited by this paper
• Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?

  2004cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification

  2003cited by this paper
• The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases.

  2003cited by this paper
• The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study

  2003cited by this paper
• The EUROPA trial

  2003cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients

  2003cited by this paper
• Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

  2003cited by this paper
• Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways

  2002cited by this paper
• [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

  2002cited by this paper
• The AT1-Type Angiotensin Receptor in Oxidative Stress and Atherogenesis

  2002cited by this paper
• The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation.

  2002cited by this paper
• The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis.

  2002cited by this paper
• Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial.

  2002cited by this paper
• Anti‐Ischemic Potential of Drugs related to the Renin‐Angiotensin System

  2001cited by this paper
• The Blood Pressure Lowering Treatment Trialists' Collaboration

  2001cited by this paper
• Angiotensin II Induces Leukocyte–Endothelial Cell Interactions In Vivo Via AT1 and AT2 Receptor–Mediated P-Selectin Upregulation

  2000cited by this paper
• Angiotensin-converting enzyme expression in human carotid artery atherosclerosis.

  2000cited by this paper
• Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

  2000cited by this paper
• Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress.

  2000cited by this paper
• The role of tubulointerstitial injury in chronic renal failure.

  2000cited by this paper
• Oxidized LDL Upregulates Angiotensin II Type 1 Receptor Expression in Cultured Human Coronary Artery Endothelial Cells: The Potential Role of Transcription Factor NF-&kgr;B

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Risk stratification in hypertension: new insights from the Framingham Study.

  2000cited by this paper
• Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.

  2000cited by this paper
• An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.

  2000cited by this paper
• Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation.

  1999cited by this paper
• Endothelial function and atherosclerosis.

  1999cited by this paper
• Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein.

  1999cited by this paper
• Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo.

  1999cited by this paper
• α1-Adrenergic Plus Angiotensin Receptor Blockade Reduces Atherosclerosis in Apolipoprotein E–Deficient Mice

  1998cited by this paper
• Alpha1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice.

  1998cited by this paper
• Vascular endothelial dysfunction.

  1997cited by this paper
• Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells.

  1997cited by this paper
• Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease.

  1996cited by this paper
• The Global Burden of Disease

  1996cited by this paper
• Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.

  1995cited by this paper
• Effect of Increased Availability of Endothelium‐Derived Nitric Oxide Precursor on Endothelium‐Dependent Vascular Relaxation in Normal Subjects and in Patients With Essential Hypertension

  1993cited by this paper
• Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits.

  1993cited by this paper
• Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement.

  1991cited by this paper
• Nitric oxide: an endogenous modulator of leukocyte adhesion.

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Circulating and tissue angiotensin systems.

  1987cited by this paper
• Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.

  1987cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper

• The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update.

  2024cites this paper
• An evaluation of the effect of pentoxifylline on blood pressure and myocardial oxidative status following intake of western diet

  2015cites this paper